On February 23, 2026, Gilead Sciences and its cell therapy subsidiary, Kite Pharma, announced a definitive agreement to acquire Arcellx, Inc. in an upfront cash-and-contingent-value transaction valued at up to $7.8 billion. The acquisition represents Gilead’s largest cell therapy deal since its foundational $11.9 billion purchase of Kite Pharma in 2017 and positions Gilead directly into the multi-billion-dollar BCMA (B-cell maturation antigen) CAR-T arena for relapsed or refractory multiple myeloma. The transaction cleared antitrust review and closed on April 28, 2026 via a tender offer and second-step merger.
Under the terms filed with the U.S. Securities and Exchange Commission (SEC Form 8-K Exhibit 99.1), Gilead agreed to acquire all outstanding shares of Arcellx for $115.00 per share in upfront cash at closing (valuing Arcellx’s upfront equity at approximately $7.1 billion), plus a non-transferable Contingent Value Right (CVR) worth up to an additional $5.00 per share. The CVR payment is contingent upon the lead investigational asset—anitocabtagene autoleucel (anito-cel)—achieving at least $6.0 billion in cumulative global net sales through December 31, 2029.
| Deal Feature | Contractual Terms & Financial Value |
|---|---|
| Acquirer / Subsidiary | Gilead Sciences, Inc. / Kite Pharma, Inc. |
| Target Company | Arcellx, Inc. (NASDAQ: ACLX) |
| Upfront Cash Price | $115.00 per share in cash (~$7.1 billion upfront equity value) |
| Contingent Value Right (CVR) | $5.00 per share in cash (up to ~$310 million additional value on the ~62 million shares outstanding) |
| CVR Milestone Trigger | ≥ $6.0 billion in cumulative global net sales of anito-cel through 2029 |
| Total Transaction Value | Up to $7.8 billion |
| Lead Asset | anitocabtagene autoleucel (anito-cel, formerly CART-ddBCMA) |
| Target Indication & Target | BCMA-directed autologous CAR-T for 4L+ relapsed/refractory multiple myeloma |
| FDA PDUFA Goal Date | December 23, 2026 (Biologics License Application submitted Q4 2025) |
| Pivotal Clinical Trial | Phase 2 iMMagine-1 (NCT05396885) |
| Primary Market Competitor | Carvykti (ciltacabtagene autoleucel — Johnson & Johnson / Legend Biotech) |
Data source: Gilead Sciences & SEC Form 8-K filings (February 23, 2026). Anito-cel is an investigational agent and was not yet approved by the FDA as of August 2026.
This deal-anatomy analysis examines the financial and legal structure of the Arcellx transaction, evaluates the clinical differentiation of anito-cel’s synthetic D-Domain binder, maps out its pending December 23, 2026 PDUFA regulatory milestone, analyzes how Gilead/Kite intends to commercialize anito-cel against Johnson & Johnson’s incumbent BCMA CAR-T, Carvykti, and details the manufacturing integration and antitrust clearance strategy across Kite's production network.
What are the exact deal terms — price per share, CVR, and total value?
Gilead’s acquisition of Arcellx reflects a carefully structured M&A format designed to manage commercial execution risk while securing full ownership of a late-stage cell therapy asset.
+-------------------------------------------------------------------------+
| GILEAD / ARCELLX TRANSACTION STRUCTURE |
| |
| Upfront Cash Payment: $115.00 / share (~$7.1 Billion Equity Value) |
| + |
| Non-Transferable CVR: $5.00 / share (~$310 Million Milestone Value) |
| [Trigger: Cumulative Global Net Sales ≥ $6.0B through Dec 31, 2029] |
| = |
| Total Potential Transaction Value: Up to ~$7.8 Billion |
+-------------------------------------------------------------------------+
Upfront Cash Premium and Valuation
The $115.00 per share upfront cash price represented a premium of approximately 68% compared to Arcellx’s 30-day volume-weighted average price (VWAP) as of February 20, 2026, the last full trading day before announcement. Gilead and Kite had previously entered into a co-development and co-commercialization partnership with Arcellx (announced December 2022, closed January 2023), under which Kite paid a $225 million upfront cash payment and Gilead made a separate $100 million equity investment, and Gilead already owned roughly 11.5% of Arcellx's outstanding common stock. The 2026 buyout consolidates 100% of global commercial rights and eliminates future profit-share splits and royalty obligations.
CVR Structure and Payout Mechanics
The non-transferable CVR offers an additional $5.00 per share to Arcellx shareholders if anito-cel reaches its commercial milestone:
- Milestone Benchmark: Cumulative global net sales of anito-cel across all approved indications reaching or exceeding $6.0 billion between closing and December 31, 2029.
- Commercial Implication: Achieving $6.0 billion in cumulative net sales over a ~3-year post-launch window requires anito-cel to achieve rapid commercial uptake (reaching an annualized run-rate of $1.5B to $2.0B+ by 2028). This milestone directly aligns CVR payout with successfully overcoming site-of-care manufacturing bottlenecks and competing head-to-head with Carvykti.
What is anito-cel and what did iMMagine-1 show?
Anitocabtagene autoleucel (anito-cel) is an autologous BCMA-directed CAR-T cell therapy engineered with a novel synthetic binding domain known as a D-Domain (ddBCMA), replacing traditional single-chain variable fragments (scFv).
Traditional scFv Binder Arcellx D-Domain Binder
+-----------------------+ +-----------------------+
| Heavy & Light Chains | | Compact, Synthetic |
| (Potential Misfolding)| | Single-Domain Protein |
+-----------------------+ +-----------------------+
| |
v v
Higher Instability & Higher Stability & High
Immunogenicity Risk Transduction Efficiency
The D-Domain Structural Advantage
Standard CAR-T constructs rely on murine or humanized scFv antibodies, which can suffer from hydrophobic misfolding, aggregation, and immune rejection by the host. Arcellx's proprietary D-Domain is a small, stable, fully synthetic binder engineered to bind BCMA with high affinity while minimizing cell-surface aggregation.
In pre-clinical and clinical evaluations, the D-Domain construct demonstrated:
- High Transduction Efficiency: Consistently yields high vector copy numbers during cell manufacturing.
- Stable Cell-Surface Expression: Reduces tonic signaling, which delays T-cell exhaustion and preserves memory T-cell phenotypes.
- Controlled Inflammatory Cytokine Profile: Minimizes rapid surge release of IL-6 and IFN-gamma, reducing high-grade neurological toxicities.
Clinical Results from the Pivotal iMMagine-1 Trial (NCT05396885)
The pivotal Phase 2 iMMagine-1 trial evaluated anito-cel in patients with relapsed or refractory multiple myeloma who received at least three prior lines of therapy, including a proteasome inhibitor (PI), an immunomodulatory drug (iMiD), and an anti-CD38 monoclonal antibody (triple-class exposed).
At the American Society of Hematology (ASH) annual meeting, updated results from iMMagine-1 demonstrated compelling clinical efficacy and safety:
- Overall Response Rate (ORR): Exceeded 95% in evaluable patients.
- Complete Response / Stringent Complete Response (CR/sCR) Rate: Reached over 65-70% with median follow-up maturing.
- Safety Profile: Notably, 0 cases of delayed movement and neurocognitive toxicities (MNT) or Parkinsonism-like symptoms were reported—a key safety differentiator compared to historical BCMA CAR-T safety signals.
- Cytokine Release Syndrome (CRS): High overall rate of Grade 1/2 CRS (>85%), but Grade 3+ CRS remained under 3%.
When is the FDA decision and what is the approved-population target?
Following the submission of the Biologics License Application (BLA) in late 2025, the U.S. FDA accepted the filing and set a Prescription Drug User Fee Act (PDUFA) target action date of December 23, 2026.
+--------------------------------------------------------------------+
| ANITO-CEL REGULATORY TIMELINE |
| |
| Dec 2022: Gilead & Arcellx Co-Development Partnership |
| Dec 2024: Pivotal iMMagine-1 Phase 2 Trial Full Enrollment |
| Q4 2025: Biologics License Application (BLA) Submitted to FDA |
| Feb 2026: Gilead Announces Buyout of Arcellx for up to $7.8B |
| Apr 28, 2026: Gilead Completes Acquisition of Arcellx |
| Dec 23, 2026: FDA PDUFA Action Date (Target Indication: 4L+ MM) |
+--------------------------------------------------------------------+
Initial Target Indication
The initial BLA submission requests FDA approval for adults with relapsed or refractory multiple myeloma who have received at least four prior lines of therapy (4L+ MM).
Planned Label Expansion Trials
To unlock the $6.0 billion CVR milestone, Gilead and Kite are already initiating label expansion studies to move anito-cel into earlier treatment lines:
- iMMagine-2 (Phase 3): Head-to-head trial comparing anito-cel against standard-of-care regimens in 2L-4L relapsed/refractory multiple myeloma.
- Outpatient Administration Protocols: Evaluating anito-cel in community hospital settings to leverage Kite's commercial cell therapy footprint.
How does anito-cel compete with J&J's Carvykti and bispecifics?
Gilead’s acquisition sets up a direct commercial showdown with Johnson & Johnson / Legend Biotech’s Carvykti (ciltacabtagene autoleucel) and Bristol Myers Squibb’s Abecma (idecabtagene vicleucel).
| Clinical / Commercial Feature | Anito-Cel (Gilead / Arcellx) | Carvykti (J&J / Legend) | Abecma (BMS / 2seventy bio) |
|---|---|---|---|
| Binding Domain | Synthetic D-Domain (ddBCMA) | Dual scFv VHH Binders | Single scFv Binder |
| FDA Status | Pending BLA (PDUFA Dec 23, 2026) | Approved (2L+ Multiple Myeloma) | Approved (2L+ Multiple Myeloma) |
| Overall Response Rate (ORR) | ~95%+ (iMMagine-1) | 98% (CARTITUDE-1) | 71% (KarMMa-3) |
| Complete Response (CR) Rate | ~65-70%+ | 83% (sCR) | 44% (KarMMa-3) |
| Delayed Neurocognitive / MNT Risk | 0 cases reported in iMMagine-1 | 3%-5% reported (Boxed Warning) | Low |
| Manufacturing Partner | Kite Pharma (Frederick, MD & El Segundo) | Janssen / Legend (Raritan, NJ) | BMS (Devens, MA) |
Key Differentiating Vectors
- Safety and Outpatient Potential: Carvykti’s FDA prescribing information carries black-box warnings for delayed neurotoxicities, movement and neurocognitive toxicities (MNT), and Guillain-Barré syndrome. Anito-cel’s zero-MNT signal in iMMagine-1 provides a major safety narrative for community oncologists considering outpatient administration.
- Kite's Manufacturing Scale: Supply-chain bottlenecks severely restricted Carvykti’s early commercial rollout. By acquiring Arcellx, Gilead transfers anito-cel manufacturing into Kite’s state-of-the-art automated viral vector and cell processing facilities in Maryland and California, which currently deliver Yescarta and Tecartus with industry-leading turnaround times (median 14-16 days).
What is Kite's manufacturing integration strategy and FTC antitrust review?
A central rationale for Gilead’s full acquisition of Arcellx—rather than maintaining a 50/50 commercial split—is the immediate operational integration of anito-cel into Kite Pharma’s commercial manufacturing infrastructure.
+-------------------------------------------------------------------------+
| KITE PHARMA CELL THERAPY INFRASTRUCTURE |
| |
| 1. Automated Viral Vector Facility (Oceanside, CA) |
| [Internalized Lentiviral / Retroviral Supply — No Third-Party CDMO] |
| + |
| 2. High-Throughput Cell Manufacturing (Frederick, MD & El Segundo, CA) |
| [14-16 Day Median Turnaround Time for Autologous Cell Processing] |
| + |
| 3. Nationwide Authorized Treatment Center Network (300+ Medical Centers)|
| [Established Buy-and-Bill & Outpatient Infusion Infrastructure] |
+-------------------------------------------------------------------------+
Eliminating Third-Party CDMO Vulnerabilities
Early cell therapy launches, including J&J/Legend's initial Carvykti commercial rollout, experienced severe slot constraints due to reliance on external contract development and manufacturing organizations (CDMOs). Kite Pharma operates fully internalized viral vector supply chains at its Oceanside, California facility and high-capacity cell processing hubs in Frederick, Maryland and El Segundo, California.
By taking 100% control of Arcellx, Gilead eliminates CDMO royalty margins and directly integrates anito-cel into Kite's automated processing lines, ensuring that commercial slot capacity can scale rapidly upon FDA approval.
Antitrust & Hart-Scott-Rodino (HSR) Clearance Context
Under the Hart-Scott-Rodino (HSR) Antitrust Improvements Act, acquisitions exceeding major dollar thresholds are evaluated by the Federal Trade Commission (FTC) and the Department of Justice (DOJ) for anti-competitive concentration. In cell therapy, antitrust scrutiny focuses on whether an acquirer holds overlapping commercial assets in the same indication.
Because Kite Pharma’s existing commercial CAR-T products—Yescarta (axicabtagene ciloleucel) and Tecartus (brexucabtagene autoleucel)—are CD19-directed agents approved for non-Hodgkin lymphoma and acute lymphoblastic leukemia, Gilead possessed zero market share in BCMA-directed multiple myeloma at the time of the deal. That absence of product overlap made the antitrust case straightforward, and the transaction cleared HSR review and closed on April 28, 2026—earlier than the Q2 2026 timeline Gilead initially guided.
Where does this fit in Gilead/Kite's cell-therapy franchise and 2026 oncology build-out?
The Arcellx transaction represents a pivotal piece in Gilead’s broader corporate strategy to expand its oncology revenue base beyond its core virology (HIV/Hepatitis C) franchise.
As outlined in the Gilead Sciences portfolio dossier, Gilead has set a strategic objective to generate more than one-third of total corporate revenue from oncology by 2030.
Gilead Oncology Build-Out (2026)
├── Commercial Hematology (CAR-T)
│ ├── Yescarta (axicabtagene ciloleucel) — Large B-cell Lymphoma
│ ├── Tecartus (brexucabtagene autoleucel) — Mantle Cell / ALL
│ └── ANITO-CEL (BCMA CAR-T) — Multiple Myeloma (PDUFA Dec 23, 2026)
├── Solid Tumor Oncology (ADC / Biologics)
│ ├── Trodelvy (sacituzumab govitecan) — TNCB / HR+/HER2- Breast / Bladder
│ └── Tubulis ADC Platform ($5B Acquisition) — Next-Gen Targeted Payloads
In our 2026 biopharma M&A by-the-numbers overview, we tracked large-cap pharmaceutical M&A transactions. Gilead’s dual acquisitions—Gilead's $5 billion Tubulis ADC acquisition for antibody-drug conjugates and Arcellx for cell therapy—demonstrate a dual-modality strategy securing dominant positions in both solid tumor ADCs and hematologic CAR-T therapies.
Furthermore, as analyzed in the CAR-T cell therapy access landscape, commercial success in autologous cell therapy requires establishing buy-and-bill reimbursement pathways, negotiating risk-sharing contracts with commercial payers, and securing broad hospital formulary access. Kite’s pre-existing network of over 300 authorized treatment centers (ATCs) nationwide provides anito-cel with an immediate commercial infrastructure upon FDA clearance.
Frequently Asked Questions
Did the Gilead-Arcellx deal close, and when?
Yes. Gilead and Arcellx announced the definitive merger agreement on February 23, 2026, and Gilead completed the acquisition on April 28, 2026 through a successful tender offer (covering approximately 77.2% of Arcellx's outstanding shares together with Gilead's existing ~11.5% stake) followed by a second-step merger. Arcellx now operates as part of Gilead's Kite Pharma cell-therapy franchise.
What is the CVR milestone and how likely is it to pay out?
The CVR pays $5.00 per share in cash if anito-cel achieves at least $6.0 billion in cumulative global net sales through December 31, 2029. Payout depends on anito-cel securing FDA approval at its December 23, 2026 PDUFA date, launching smoothly in 2027, and achieving rapid market penetration in both 4L+ and earlier-line multiple myeloma.
Is anito-cel approved yet, and for which line of therapy?
No. Anito-cel is an investigational drug and has not been approved by the FDA or any global regulatory agency. The BLA is under active review with an FDA PDUFA goal date of December 23, 2026 for adult patients with relapsed or refractory multiple myeloma after four or more prior lines of therapy.
How does anito-cel compare to BCMA bispecific antibodies like Tecvayli and Elrexfio?
Off-the-shelf BCMA bispecific antibodies (e.g., J&J's Tecvayli and Pfizer's Elrexfio) offer immediate availability without the 2-to-3 week manufacturing delay of CAR-T. However, bispecifics require continuous weekly or biweekly step-up dosing until disease progression, leading to cumulative T-cell exhaustion and infection risk. Anito-cel provides a single-infusion "one and done" treatment, offering durable treatment-free remissions.
Why is anito-cel's synthetic D-Domain binding construct clinically significant?
Arcellx's proprietary D-Domain replaces traditional murine scFv antibody fragments with a small, highly stable, synthetic protein binder. In clinical trials, this construct prevented hydrophobic misfolding and cell surface aggregation, resulting in high transduction efficiency during manufacturing and eliminating severe delayed neurocognitive toxicities (MNT) in pivotal trials.
Sources
- Gilead Sciences, Inc.: Gilead Sciences to Acquire Arcellx to Maximize Long-Term Potential of Anito-Cel in Multiple Myeloma. Press Release (February 23, 2026). URL:
https://www.gilead.com/news/news-details/2026/gilead-sciences-to-acquire-arcellx - U.S. Securities and Exchange Commission (SEC): Gilead Sciences, Inc. Form 8-K Current Report (Exhibit 99.1 Agreement and Plan of Merger). Filed February 23, 2026. URL:
https://www.sec.gov/edgar - ClinicalTrials.gov: iMMagine-1: A Study of Anitocabtagene Autoleucel (Anito-cel) in Adults With Relapsed or Refractory Multiple Myeloma. Identifier:
NCT05396885. URL:https://clinicaltrials.gov/study/NCT05396885 - FierceBiotech: Gilead inks $7.8B Arcellx buyout to steer CAR-T into J&J showdown. Published February 23, 2026. URL:
https://www.fiercebiotech.com/biotech/gilead-inks-78b-arcellx-buyout-steer-car-t-jj-showdown - U.S. Food and Drug Administration (FDA): Carvykti (ciltacabtagene autoleucel) Prescribing Information & Neurotoxicity Warnings. URL:
https://www.fda.gov/vaccines-blood-biologics/cellular-gene-therapy-products/carvykti
